Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772145 | 1.00 | CACNA1F (0.39) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6198625 | 0.91 | ADRA1D (0.45) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6196834 | 0.82 | ADRA1D (0.51) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7674379 | 0.82 | ADRA1D (0.51) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6715576 | 0.81 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6898111 | 0.80 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL7162576 | 0.79 | ADRA1D (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6193641 | 0.79 | ADRA1D (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6715316 | 0.78 | CACNA1F (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6214417 | 0.78 | ADRA1D (0.38) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | CACNA1F 4253/4885CACNA1D 3141/4885CACNA1S 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.